AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2200966
Drug: Corticosteroids (prednisolon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (prednisolon 2 mg/kg/day IV initially, then prednisone orally for 3 weeks)
Trial: 19770624
Drug: ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10 mg daily
Trial: 15196292
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous eletriptan (n = 24)
Trial: 15196292
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of sumatriptan (6 mg subcutaneously, n = 18)
Trial: 11602853
Drug: Basiliximab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (20 mg, intravenously on days 0 and 4)
Trial: 899874
Drug: Doleron (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doleron (combination tablet containing propoxyphene chloride, acetyl salicylic acid, and phenazone) taken with a standardized breakfast meal
Trial: 899874
Drug: Doleron (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doleron (combination tablet containing propoxyphene chloride, acetyl salicylic acid, and phenazone) taken on an empty stomach
Trial: 899874
Drug: Doleron (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doleron (combination tablet containing propoxyphene chloride, acetyl salicylic acid, and phenazone)
Trial: 25575246
Drug: AeroEclipse II
RxNorm normalized name: AeroEclipse II BAN Nebulizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AeroEclipse II BAN nebulizer with 20-second inhalation
Trial: 25575246
Drug: EW nebulizer
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EW nebulizer with 20-second inhalation
Trial: 3898920
Drug: Continuous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous low-dose intravenous infusion of lidocaine (2 mg/kg) for 24 hours after surgery
Trial: 24989775
Drug: GAL-021 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAL-021 at 0.96 mg kg(‐1) h(‐1) for 1 h
Trial: 22527222
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PAI‐1 variants with known genetic thrombophilias
Trial: 31595565
Drug: Methazolamide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methazolamide (100 mg twice daily)
Trial: 26689783
Drug: Rivaroxaban (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (2.5 mg twice daily)
Trial: 24699093
Drug: Gadolinium contrast
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium contrast agent administration
Trial: 19097848
Drug: 10-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day antibiotic therapy
Trial: 20185560
Drug: 14-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day antibiotic therapy
Trial: 6274471
Drug: suloctidil 300
RxNorm normalized name: suloctidil
DrugBank: Suloctidil (DB13340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suloctidil 300 mg per day
Trial: 28643922
Drug: Growing subjects
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Growing subjects (G)
Trial: 28643922
Drug: Overall comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall comparison of G vs NG
Trial: 23350589
Drug: Corticocancellous allograft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticocancellous allograft block with saline solution
Trial: 23350589
Drug: Standard guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard guided bone regeneration with saline solution
Trial: 22732511
Drug: Antibiotics alone;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics alone; n=54
Trial: 22732511
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus albumin; n=56
Trial: 16143188
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment (5 years)
Trial: 12403182
Drug: Active modalities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active modalities (various treatments)
Trial: 12403182
Drug: Anterior repositioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior repositioning appliance therapy
Trial: 12403182
Drug: Flat plane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flat plane splint therapy
Trial: 7805235
Drug: Zankiren HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zankiren HCl (10 to 250 mg)
Trial: 7250172
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of sotalol and hydrochlorothiazide (6.4:1 ratio)
Trial: 25862350
Drug: Capecitabine 825
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825 mg/m² twice daily on days 1-21 every 4 weeks
Trial: 25862350
Drug: S-1 40-60
RxNorm normalized name: DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER (40/60 W/W; 1000000 PA.S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 40-60 mg twice daily on days 1-28 every 6 weeks
Trial: 23799280
Drug: Ibuprofen (200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (200-400 mg)
Trial: 7863248
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 300 mg/d nizatidine (n = 90)
Trial: 8212757
Drug: nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nizatidine 150 mg nocte (n = 116) in prophylactic trial
Trial: 8212757
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 150 mg nizatidine daily (n = 121) in prophylactic trial
Trial: 3535187
Drug: Daily short
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily short course chemotherapy (6-month) with regimens containing streptomycin, isoniazid, rifampicin, and pyrazinamide in the initial phase; isoniazid plus rifampicin or isoniazid plus rifampicin and/or pyrazinamide in the continuation phase.
Trial: 3535187
Drug: Daily short
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily short course chemotherapy (6-month)
Trial: 31318258
Drug: Perceived momentum
RxNorm normalized name: aspirin / phenyltoloxamine citrate Oral Tablet [Momentum tradename]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived momentum in sequential events
Trial: 31318258
Drug: Events that
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Events that break streaks (e.g., incorrect guesses)
Trial: 31004325
Drug: Needle-free insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Needle-free insulin injector
Trial: 24089542
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin pen
Trial: 28734823
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg daily for up to 28 days
Trial: 14668658
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection (control group)
Trial: 9267946
Drug: Dopexamine infusion
RxNorm normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine infusion at 6.0 microg/kg/min
Trial: 9267946
Drug: Dopexamine infusion
RxNorm normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine infusion at 3.0 microg/kg/min
Trial: 9267946
Drug: Dopexamine infusion
RxNorm normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine infusion at all rates (0.75, 1.5, 3.0, and 6.0 microg/kg/min)
Trial: 3302866
Drug: Cefotaxime IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime IV (100 mg.kg‐1 D‐1) plus netilmicin (4 mg.kg‐1 D‐1)
Trial: 3302866
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid IV (100/10 mg.kg‐1 D‐1) plus netilmicin (4 mg.kg‐1 D‐1)
Trial: 30110194
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg
Trial: 27269741
Drug: Nivolumab 1
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1 mg/kg plus ipilimumab 1 mg/kg
Trial: 27622997
Drug: Nivolumab 1
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg
Trial: 30110194
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg
Trial: 18680975
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy schemes
Trial: 12829908
Drug: Daclizumab 1
RxNorm normalized name: daclizumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 1 mg/kg immediately after liver transplantation
Trial: 10791000
Drug: Conventional full-dose
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional full-dose docetaxel (FD) 60 mg/m2 every 3 or 4 weeks (group I)
Trial: 10791000
Drug: Low-dose weekly
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose weekly docetaxel (LD) 20-30 mg/m2 every week (group II)
Trial: 10791000
Drug: Low-dose weekly
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose weekly docetaxel (LD) 20-30 mg/m2 weekly with oral 5'-DFUR 600-1,200 mg per day (LD + D, group III)
Trial: 20664343
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs (ibuprofen 800 mg twice a day for 10 days)
Trial: 27196998
Drug: Morphine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine administration
Trial: 31977567
Drug: Lanreotide autogel/depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide autogel/depot 120 mg
Trial: 25249172
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone iodine solution (0.5 mg/mL)
Trial: 19186714
Drug: Routine chemotherapeutic
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine chemotherapeutic program of western medicine
Trial: 3930683
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 1-[13C]acetate
Trial: 3930683
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of 1-[13C]acetate
Trial: 31514191
Drug: Physiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy plus intra-articular methylprednisolone injection
Trial: 23970941
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (8 ounces daily for 4 weeks)
Trial: 23970941
Drug: Placebo drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink (flavor-matched, 8 ounces daily for 4 weeks)
Trial: 8630199
Drug: Mexiletine (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (450 mg/day)
Trial: 6331138
Drug: Cronassial (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cronassial (20 mg daily intramuscularly for 6 weeks)
Trial: 25475245
Drug: Individualised self‐management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised self‐management support for patients and feedback on use of evidence‐based HF therapies (EBT) to physicians.
Trial: 25475245
Drug: Patient education,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education, support, and self‐management training for diet and medication adherence by a trained nurse through 11 interactive sessions over a 4‐month period.
Trial: 20637971
Drug: Linagliptin 10
RxNorm normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 10 mg single dose
Trial: 20637971
Drug: Linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 5 mg multiple doses
Trial: 20637971
Drug: Linagliptin 10
RxNorm normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 10 mg multiple doses
Trial: 20637971
Drug: Linagliptin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin (various doses)
Trial: 11952447
Drug: Group 0
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 0 (modified supine position immediately after spinal injection)
Trial: 8592998
Drug: Standard co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard co-trimoxazole therapy without monitoring (5 mg/kg trimethoprim and 25 mg/kg sulfamethoxazole every 6 h for 2 days, then every 8 h for 21 days)
Trial: 368306
Drug: 2.5 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 percent solution (double blind study)
Trial: 368306
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of drugs (protocol at United Hospitals Medical Center)
Trial: 26798083
Drug: Injection volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection volume up to 800 µL
Trial: 19281585
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg mifepristone daily for three months
Trial: 17229243
Drug: Immediate-release omeprazole
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release omeprazole (IR-OME)
Trial: 12001978
Drug: Advice to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice to increase soluble fibre intake to 8.0 g day(‐1) (fruit, vegetables and oats)
Trial: 27804310
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral mifepristone plus 400 μg misoprostol per vaginally concurrently (group A)
Trial: 27804310
Drug: Misoprostol administered
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol administered after 48 hours (group B)
Trial: 21169226
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (1200 mg/d)
Trial: 18460568
Drug: Triflusal (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal (two dose levels)
Trial: 8873586
Drug: Desmin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmin 100 mg once daily by subcutaneous route (36 patients)
Trial: 8873586
Drug: Desmin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmin 100 mg twice a day by subcutaneous route (33 patients)
Trial: 8873586
Drug: Desmin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmin 200 mg once daily by intramuscular route (31 patients)
Trial: 2895125
Drug: Nizatidine 75
RxNorm normalized name: nizatidine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 75 mg bid
Trial: 2567740
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg qid
Trial: 18001246
Drug: Sub-tenon triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sub-tenon triamcinolone acetonide (STA) injection
Trial: 16250568
Drug: Emdogain (Biora)
RxNorm normalized name: Biore
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emdogain (Biora) combined with surgical treatment (SPP flap)
Trial: 16250568
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment alone (SPP)
Trial: 12551742
Drug: Cholecystokinin tetrapeptide
RxNorm normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecystokinin tetrapeptide (CCK‐4) infusion
Trial: 7975833
Drug: HIV‐1LAV gp160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV‐1LAV gp160 live recombinant vaccinia virus priming followed by a booster injection with a baculovirus‐expressed HIV‐1LAV recombinant gp160 candidate vaccine
Trial: 29033099
Drug: Cabazitaxel (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (25 mg/m2 IV every 21 days) plus prednisone (10 mg daily)
Trial: 21555815
Drug: Drug Conservation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug Conservation (DC) arm
Trial: 17256437
Drug: Peripheral parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral parenteral nutrition (PPN) for 7 days perioperatively
Trial: 17256437
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (oral diet reintroduction on the fourth postoperative day)
Trial: 10862159
Drug: Amiloride nebulized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride nebulized solution three times daily for 6 months
Trial: 10862159
Drug: Placebo nebulized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nebulized solution three times daily for 6 months
Trial: 28903966
Drug: Selective laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective laser trabeculoplasty (SLT) followed by conventional medical therapy as required
Trial: 31488427
Drug: Topical medication
RxNorm normalized name: Procto-Med Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical medication
Trial: 16003515
Drug: carteolol 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carteolol 2% regular twice daily for 2 months
Trial: 8605790
Drug: Pentoxifylline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1 mg/kg followed by an infusion of 1.5 mg/kg/hr for 24 hrs)
Trial: 3097109
Drug: Astemizole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (10 mg)
Trial: 1401653
Drug: Terfenadine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (60 mg)
Trial: 6128019
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antihistamine)
Trial: 28922099
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, Lactobacillus fermentum; 2 × 10^9 colony‐forming units/g each; n = 20)
Trial: 15572850
Drug: Oral zafirlukast
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral zafirlukast (40 mg/day) in addition to budesonide for 6 weeks
Trial: 8995587
Drug: Suramin treatment
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin treatment
Trial: 12087908
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment program (synchronous plasmapheresis, large-dose methotrexate and methylprednisolone)
Trial: 7780243
Drug: High cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cholesterol formula (30 mg/dl cholesterol)
Trial: 7780243
Drug: Breast milk
RxNorm normalized name: BREAST MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast milk (mean cholesterol content 15.3 mg/dl)
Trial: 2141104
Drug: Salbutamol, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol, 2.5 mg
Trial: 2141104
Drug: Ipratropium, 0.250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium, 0.250 mg
Trial: 30945991
Drug: Weight training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight training combined with pelvic floor muscle training (moderate intensity, twice a week for 12 weeks)
Trial: 30276500
Drug: Erenumab 70
RxNorm normalized name: Erenumab 70 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 70 mg (CM)
Trial: 25688120
Drug: Standard-dose temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose temozolomide
Trial: 25151418
Drug: Augmented therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented therapy (parent training, stimulant medication, and risperidone)
Trial: 25151418
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy (parent training, stimulant medication, and placebo)
Trial: 22376026
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine gluconate (CHX) oral swabbing four times/day